 |
11 Diseases |  |
0 Trials |
|
0 Trials |  |
25 News |  |
- | oral calcitonin (SMC021) / Novo Nordisk
Journal: Longitudinal stability of molecular endotypes of knee osteoarthritis patients. (Pubmed Central) - Dec 21, 2024
Our study showed for the first time that more than half of KOA participants exhibited a longitudinally stable endotype, highlighting the applicability of biomarker-based endotyping in a clinical trial setting.
- oral calcitonin (SMC021) / Novo Nordisk
Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2958;
P3
Further research is needed to substantiate the observed findings and to evaluate the underlying pathways that may mediate these associations. Table: Concomitant use and associations with change in WOMAC pain/JSW over 2 year (adjusted for baseline variables) C. Miller: NBCD, 3; M. Baker: Mobility Bio, 8, Nesos, 2; P. Alexandersen: NBCD, 3; A. Mondrag
- oral calcitonin (SMC021) / Novo Nordisk
From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes (Room 6F/6C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_1697;
Identifying these endotypes could facilitate the development of more precise treatments that are designed to address specific causes of OA in distinct patient subgroups. Table 1
- | cagrilintide (AM833) / Novo Nordisk
Preclinical, Journal: Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. (Pubmed Central) - Oct 16, 2022
These are salmon calcitonin-based and have shown preclinical potential; however, how and if they differentiate from amylin-derived molecules remain to be studied...In summary, both KBP-336 and cagrilintide are DACRAs, however with KBP-336 being biased towards the CTR resulting in a different receptor activation balance. Interestingly, KBP-336 showed superior long-term efficacy on both weight loss and glucose control, supporting relevance of the receptor balance, and highlighting KBP-336 as a promising agent for the treatment of obesity and T2D.
- oral calcitonin (SMC021) / Novo Nordisk
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2261;
P3
Use of antihistamines was associated with reduced structural progression in knee OA. Further research evaluating the role of antihistamines in OA is needed to further characterize this observation
- oral calcitonin (SMC021) / Novo Nordisk
Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials (South Philly Stage) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1472;
P3
Use of antihistamines was associated with reduced structural progression in knee OA. Further research evaluating the role of antihistamines in OA is needed to further characterize this observation
- oral calcitonin (SMC021) / Novo Nordisk
HIGH LEVELS OF TYPE II COLLAGEN DEGRADATION (C2M) ASSOCIATED WITH RESPONSE TO SALMON CALCITONIN: A POST-HOC ANALYSIS OF SMC STUDY () - Apr 29, 2022 - Abstract #OARSI2022OARSI_274;
P3
Oral salmon calcitonin (sCT) initially showed beneficial effects in preclinical and clinical phase I and II trials, while it failed to demonstrate significant therapeutic benefits to patients in a randomized, placebo-controlled, double-blinded, and multicentre, phase III clinical trial (SMC study: CSMC021C2301/ NCT00486434). In this study, we conducted a post-hoc analysis of a single-site sub-population of the failed phase III clinical trial with three serological biomarkers: C2M (an MMP-derived type II collagen degradation biomarker), CPRM (an MMP-mediated C-Reaction Protein biomarker representing the inflammation of tissue) and C10C (a Cathepsin-K degraded type X collagen biomarker) to investigate if patients with high or low biomarker levels response differently to sCT.
- oral calcitonin (SMC021) / Novo Nordisk
Antihistamine use and structural progression of knee OA: A Post-Hoc analysis of two phase III clinical trials (Auditorium 15) - Apr 4, 2022 - Abstract #EULAR2022EULAR_969;
P3
Use of antihistamines was associated with reduced structural progression in knee OA. Further research evaluating the role of antihistamines in OA is needed to further characterize this observation.
- || oral calcitonin (SMC021) / Novo Nordisk
unosmlre via NodeXL https://t.co/AO0jPq7SBa @nebraskasower @thartman2u @jeremyhl @unosmlre @michaelbathurst @westurner @mpweirdopodcast @crockettlibby @owhnews @drjrmarcelin Top hashtags: #smprofs #prprofs #smc2021 #smle2022 #smmm2020 #socialmedia #data #pr / (Twitter) - Aug 2, 2021
- | oral calcitonin (SMC021) / Novo Nordisk
Journal: A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis. (Pubmed Central) - Jul 1, 2021
Further research evaluating the role of antihistamines in OA is needed to further characterize this observation. Serum/plasma level of type II collagen formation, PRO-C2, may be an objective indicator of a low cartilage repair endotype, displaying radiographic progression and superior response to a proanabolic drug.
- oral calcitonin (SMC021) / Novo Nordisk
[VIRTUAL] A novel serological pharmacodynamic biomarker assessing type II collagen degradation in osteoarthritis patients () - May 3, 2021 - Abstract #OARSI2021OARSI_109;
Studies have indicated that MMP-13 plays a critical role in type II collagen degradation in articular cartilage in OA and hence, T2CM may serve as a potential pharmacodynamic biomarker candidate in OA. The aim of this study was to evaluate the pharmacodynamic property of T2CM in OA patients treated with oral salmon calcitonin compared to placebo.
- oral calcitonin (SMC021) / Emisphere Technologies
A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment (Hall B5) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3152;
P3
Low PRO-C2 may provide a measure of an OA endotype with low background cartilage formation (at baseline) and higher capacity for repair when treated with a potential cartilage anabolic drug. Fig.
- oral calcitonin (SMC021) / Emisphere Technologies
Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA – a Post-Hoc Analysis of Data from Two Randomized Controlled Trials (Thomas Murphy Ballroom 3 & 4) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_1920;
P3
A marked structure-symptoms discordance was found in OA patients with ADD and BP, while a statistically significant correlation was seen in matched controls without ADD or BP. The results suggest that exclusion of trial patients with anxiety and depression and/or back pain in medical history may improve the accuracy of pain reporting in clinical OA trials.
- | oral calcitonin (SMC021) / Novo Nordisk
Trial termination: Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study) (clinicaltrials.gov) - Aug 12, 2012
P3, N=1030, Terminated, Sponsor: Nordic Bioscience A/S
The results suggest that exclusion of trial patients with anxiety and depression and/or back pain in medical history may improve the accuracy of pain reporting in clinical OA trials. Completed --> Terminated; Male subjects were terminated due to an imbalance in prostate cancer events
- ||||||| oral calcitonin (SMC021) / Novo Nordisk
Trial completion: A Study to Evaluate Oral Salmon Calcitonin in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D (clinicaltrials.gov) - Mar 21, 2012
P3, N=4665, Completed, Sponsor: Nordic Bioscience A/S
Completed --> Terminated; Male subjects were terminated due to an imbalance in prostate cancer events Active, not recruiting --> Completed